



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/495</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/04261 (43) International Publication Date: 5 February 1998 (05.02.98)</p>
<p>(21) International Application Number: PCT/US97/05940 (22) International Filing Date: 10 April 1997 (10.04.97) (30) Priority Data: 60/022,836 31 July 1996 (31.07.96) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; 5 Research Parkway, Wallingford, CT 06492 (US). (72) Inventors: MARCUS, Ronald, N.; 99 West Meadow Road, Hamden, CT 06518 (US). SUSSMAN, Neil, M.; 205 Blake Road, Hamden, CT 06517 (US). (74) Agent: RYAN, Richard, P.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: NEFAZODONE: USE IN MIGRAINE PROPHYLAXIS</p>		
<p>(57) Abstract</p> <p>Nefazodone and its pharmaceutically acceptable salts are useful in prophylactic treatment of recurrent headache disorders, in particular vascular and especially migraine headaches.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEFAZODONE: USE IN MIGRAINE PROPHYLAXIS

Field of Invention

This invention relates to the prophylactic treatment of vascular headaches, especially migraine, with nefazodone.


5

Background of the Invention

This invention is concerned with a drug bio-affecting body-treating process which employs the compound 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one or a pharmaceutically acceptable acid addition salt thereof.

10

This compound has the following structural formula (I)



(I)

and is known as nefazodone. The hydrochloride salt has been referred to in the literature as MJ 13754-1 and as BMY 13754, as well as nefazodone hydrochloride, which is the United States Adopted Name (USAN); refer to
15 "USP Dictionary of USAN and International Drug Names," 1995, p. 459.

Synthesis of nefazodone and close analogs and disclosure of its pharmacology are described in the following patents and publications.

1. Temple, et al, U.S. 4,338,317 issued July 6, 1982.
- 20 2. Gammans, U.S. 5,116,852, issued May 26, 1992.
3. D.P. Taylor, et al, "Nefazodone Hydrochloride," Drugs of the Future, 12(8) pp. 758-759 (1987).

4. A. Eison, et al, "Nefazodone: Preclinical Pharmacology of a New Antidepressant," Psychopharmacology Bulletin, 26(3) pp. 311,315 (1990).

5 Clinical studies of nefazodone have indicated its usefulness as an antidepressant agent and nefazodone hydrochloride has been approved by the U.S. Food and Drug Administration for use in treating depressed patients. Nefazodone also appears to have sleep normalizing properties in a human population. This contrasts with effects on sleep seen for other antidepressant drugs.

10 The method of the present invention can be distinguished from the above prior art in that it is directed to a distinct patient population characterized by a disease state different from that related to depression disclosed in this prior art.

15 For patients suffering from recurrent vascular headaches such as migraine, cluster, or chronic daily headaches, three treatment considerations are important.

1. No single therapy is effective in all patients with the same type of headache.
- 20 2. Prophylaxis is valuable in chronic muscle-contraction, migraine and cluster headaches.
3. Drug dependence potential should be taken into account in selection of a prophylactic headache medication.


25 Agents that have found some use in prophylactic headache therapy comprise ergot alkaloids, beta-blocking agents, calcium-channel blocking agents, non-steroidal antiinflammatory drugs, methysergide (a serotonin antagonist), divalproex sodium (Depakote, an antiepilepsy agent), and antidepressants. With antidepressant agents, the relationship between depression and chronic headache is not known but some antidepressant drugs have been reported to be effective in the treatment of migraine and
30 chronic headache disorders.

Nappi, *et al.* in *Headache*, 30:438-444, 1990, reported a comparative treatment study in patients with chronic headache as well as depression. Both ritanserin and amitriptyline appeared to be effective in treating this patient population although the antimigraine response was reported to be relatively independent of the antidepressant activity.

Foster, *et al.* in *Headache*, 34:587-589, 1994, reported that paroxetine appeared to be effective in the treatment of chronic daily headache. Co-existing depression was not an entry criterion and was not evaluated in this study population. Amitriptyline, a tricyclic antidepressant, has been reported to be effective in non-depressed patients with severe migraine and in depressed patients with less severe migraine.

While the use of nefazodone for prophylactic treatment of recurrent headache is novel, other antidepressant agents have been disclosed as being used in the prophylactic treatment of headache disorders. There is, however, no direct connection between headache prophylaxis activity and antidepressant activity, as some potent antidepressants have not been shown to have prophylactic headache activity. The differences in the comparative efficacy of agents that act at different points in the serotonin system may be attributed to the pathophysiology of recurring headaches. It is possible that nefazodone possesses important clinical distinctions from other available treatments, because of its dual effects on serotonergic transmission (i.e., 5-HT₂ antagonism and 5-HT uptake inhibition) and norepinephrine uptake.

The most relevant antidepressant drug for comparison to nefazodone would seem to be trazodone, with its structure (II) containing a meta-chlorophenylpiperazine moiety



(II)

similar to nefazodone.

Meta-chlorophenylpiperazine (MCP) itself has been reported to be an initiator of migraine (see e.g. Silberstein, et al. and Spierings in Headache, 32:242-244, 1992). Trazodone has been reported to induce migraine attack, presumably via release of MCP (see Workman, et al., Am. J. Psychiatry, 149/5:712-713, 1992).

We believe that upon consideration of all applicable prior art there is no teaching or suggestion that nefazodone would be useful in the prophylactic treatment of recurrent headache disorders.

Summary of the Invention

The process of the present invention is intended for the prophylactic treatment of recurrent headache disorders of which vascular headache, such as migraine and cluster; and chronic daily headache are specific headaches to be treated. The process essentially involves administration of nefazodone, or a pharmaceutically acceptable acid addition salt thereof, to one in need of such treatment. For use in the instant process, oral administration of nefazodone hydrochloride ranges from about 100 to 600 mg per day. Administration of about 200 to 500 mg per day in divided doses is anticipated as being the preferred dosage regimen. While various treatments have been employed for headache prophylaxis, it is possible that nefazodone possesses important clinical distinctions from other available treatments because of its dual effects on serotonergic transmission and norepinephrine uptake.

Detailed Description of the Invention

Chronic recurrent headaches, particularly those of the vascular category, usually lead to patient consultation with a physician because of frequency and pain intensity which is often incapacitating. Although there is no universally accepted classification system for headache, recurrent headache disorders, for purposes of the present invention, refers mainly to vascular headaches, such as migraine and cluster headaches, and to chronic daily headache whether vascular, muscle tension, or vascular-muscle in nature. It is an object of the present invention to treat all recurrent headache disorders by prophylactic administration of an effective amount of nefazodone or one of its pharmaceutically acceptable salts or hydrates.

While various prophylactic treatments have been employed in patients suffering from recurrent headache disorders, clinical results in general appear to be variable and, for many agents, undesirable side-effects limit their use. It is, therefore, a further objective of the present invention to provide a method of prophylactic treatment that minimizes undesirable side-effects. To that end, nefazodone is relatively free of adverse effects, particularly lacking adverse effects with respect to sleep and sexual responsiveness.

It has now been clinically observed that prophylactic administration of nefazodone alleviates the frequency and/or intensity of recurrent headache disorders.

In a study of approximately 20 patients suffering from recurring vascular headaches who either did not tolerate or were unresponsive to tricyclic antidepressants or selective serotonin reuptake inhibitors, nefazodone therapy was initiated. Improvement across the group was observed with respect to both frequency of headaches and level of tolerance of the headaches. In addition, nefazodone was well tolerated by the patient group.

In another study, seven patients suffering from chronic daily headaches of the mixed migraine/tension-type headache disorder were treated with nefazodone. The patients were given nefazodone in the range of 150-250 mg once a day or a divided 300 mg dose twice a day. Clinical experience with patients afflicted with chronic daily headaches has led to a commonly held opinion that any improvement at all in this patient population is a major achievement. Nefazodone treatment resulted in decreases in pain severity and/or headache frequency. Also indicative of nefazodone's headache prophylaxis was a decrease in concomitant pain reliever use by the study population while being given nefazodone.

Currently, studies are being planned to continue the evaluation of nefazodone's utility in the prophylactic treatment of recurrent headache disorders.

The method of the present invention essentially involves administration of nefazodone, or a pharmaceutically acceptable acid

addition salt thereof, to a patient in need of such treatment.

Pharmaceutically acceptable acid addition salts of nefazodone and methods of pharmaceutical formulation are described in the patent of Temple, et al, U.S. 4,338,317, which is incorporated herein in its entirety by
5 reference.

Administration of nefazodone hydrochloride according to the present invention may be by the parenteral, oral, or rectal routes. The oral route is preferred, however. The clinical dosage for alleviation of headache disorders is expected to be around 300 mg per day, generally in the 200 to
10 600 mg range and preferably in the range of 200 to 500 mg per day. Since the dosage should be tailored to the individual patient, the usual practice is to commence with a dose of about 50 mg administered once or twice a day and then to increase the dose every week by 50 to 100 mg at each dosage time until the desired response is observed or until the patient exhibits side
15 effects.

Claims

1. A method for prophylactic treatment of recurrent headache disorders which comprises administering a non-toxic therapeutically effective dose of nefazodone or a pharmaceutically acceptable acid addition salt thereof to a
5 patient in need of such treatment.
2. The method of claim 1 wherein nefazodone hydrochloride is employed and dosage is by the oral route.
3. The method of claim 1 wherein vascular headache is the specific recurrent headache disorder afflicting said patient.
- 10 4. The method of claim 3 wherein migraine headache is the specific vascular headache afflicting said patient.
5. The method of claim 1 wherein chronic daily headache is the specific recurrent headache disorder afflicting said patient.
- 15 6. The method of claim 2, 3, 4, or 5 wherein said patient is an adult and a daily dose of from about 100 mg to 600 mg is employed.
7. The method of claim 6 wherein said daily dose is divided and administered b.i.d.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05940

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/495

US CL :514/253

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/253

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN (REGISTRY, CA, BIOSIS, MEDLINE, DERWENT DRUG FILE)
search terms: migraine, headache, pain, analgesia, nociception, algesia

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Chemical Abstracts, Volume 116, Number 17, Potentiation of opioid analgesia by the antidepressant nefazodone. April 1992. abstract no. 166183a. PICK et al. page 62. Eur. J. Pharmacol. 211(3). 375-381, see entire document.	1-7

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 14 MAY 1997	Date of mailing of the international search report 05 JUN 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer WILLIAM JARVIS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235